JAMES F. LIST, M.D., PH.D.

GLOBAL THERAPEUTIC AREA HEAD
CARDIOVASCULAR & METABOLISM

James F. List, M.D., Ph.D., is the Global Therapeutic Area Head of Cardiovascular & Metabolism (CVM), leading a global team focused on creating new solutions for improving cardiovascular and diabetes care and disease interception. Jim has end-to-end research and development responsibility for the Janssen CVM portfolio, including drug discovery, clinical development, and external innovation. Jim joined Janssen in 2014.

Prior to joining Janssen, James served with Bristol-Myers Squibb as Vice President, Diabetes Development, with responsibility for the diabetes joint venture alliance with AstraZeneca.

Earlier in his career, James was a faculty member of the Harvard Medical School in Boston, Massachusetts,with clinical responsibilities in General Endocrinology and Thyroid. He graduated from Stanford University in Stanford, California, and completed his M.D. and Ph.D. from the University of Minnesota in Minneapolis, Minnesota. He completed his medical training at Brigham and Women’s Hospital, Boston Children’s Hospital and the Massachusetts General Hospital, all in Boston, Massachusetts, and is board certified in Internal Medicine, Pediatrics and Endocrinology.

MARK ERION, PH.D.

GLOBAL VICE PRESIDENT AND INTERNAL & EXTERNAL DISCOVERY HEAD
CARDIOVASCULAR AND METABOLISM

Mark Erion, Ph.D., is Global Vice President and Internal & External Discovery Head of Cardiovascular and Metabolism. Mark manages a team of 85 biologists, which works closely with other Janssen functions to discover and advance drug candidates into development through internal discovery or licensing opportunities for various cardiovascular and metabolic diseases. Mark is also responsible for the Metabolism Disease Area Stronghold, focusing on strategy and early pipeline targeting kidney disease, obesity, and non-alcoholic steatohepatitis. In addition, Mark leads external innovation strategy for drug discovery in collaboration with academic leaders and biotechs, which operates out of J&J’s Innovation Centers.

Mark joined Janssen in 2016 from Merck, where he was Vice President and Therapeutic Area Biology Head for Cardiovascular and Diabetes. In his six years at Merck, Mark also served as Vice President and Discovery & Preclinical Site Head of Merck Research Laboratories Kenilworth, and Vice President and Worldwide Discovery Head for Diabetes and Obesity.

Mark earned his Ph.D. in chemistry from Cornell University and completed a National Institutes of Health postdoctoral fellowship at the Massachusetts Institute of Technology.

JOHN (JACK) LAWRENCE, M.D.

GLOBAL DEVELOPMENT HEAD
CARDIOVASCULAR & METABOLISM

John (Jack) Lawrence, M.D., is the Global Development Head of Cardiovascular & Metabolism (CVM) for Janssen Pharmaceutical Companies of Johnson & Johnson.

Jack is responsible for late stage clinical development for all cardiovascular and metabolic assets that transition from discovery and early development to late development. He also drives strategy for the identification and selection of promising external assets across the portfolio.

Jack is a trained cardiologist with specialty training in cardiac electrophysiology. He began his clinical practice at the John Hopkins University School of Medicine, treating patients with heart rhythm abnormalities. Prior to joining Janssen, he spent 17 years at Bristol-Myers Squibb where he served as vice president of cardiovascular business development. Most recently, he served as the chief medical officer for Portola Pharmaceutical where he was responsible for leading all product development, clinical and regulatory strategies and product approvals.

Jack received his Doctor of Medicine at the University of Virginia School of Medicine and completed his residency in Internal Medicine at the University of North Carolina School of Medicine. Prior to that, he earned his Bachelor of Science degree in Biomedical Engineering at Brown University and his Master of Science degree in Electrical Engineering at the Massachusetts Institute of Technology.